Toledo
in inflammation

- Novel, SIK target
- Dual action on inflammation
- Preclinical models show strong activity
- GLPG3970 in multiple PoC studies

[1] Global Data ; [2] Nikpour et al Curr Opin Rheumatol. 2014; [3] Denton et al Lancet 2017

Can we make a difference?



Reference: Data on file

Galápagos

Restoring the immune balance



Galápagos

Dual activity confirmed

In both macrophages & dendritic cells



Galápagos

Potential broad application in inflammation



Broad cellular activity with Toledo
on both innate and adaptive immune cells

Galápagos

Innovative chemistry

>3,000 molecules synthesized

10 chemical series investigated

Multiple selectivity profiles

4 patents filed, exemplifying **~ 1,000** compounds

>200 dedicated FTE years since 2014





Galápagos

Robust activity *in vivo* in 3 IBD models



###p < 0.001
**p < 0.05; ***p < 0.001 (vs diseased)*
AUC: area under the curve

Galápagos

Impacting both sides of the balance *in vivo*

Macrophage phenotypes in IBD colon tissue
(T-cell transfer model)



Pro-inflammatory macrophage reduced

Immunoregulatory macrophage induced

****p<0.001 (vs diseased)*

Galápagos

Toledo portfolio



Promising and broad *in vivo* activity



Dual activity confirmed *ex vivo*

Phase 1 GLPG3970

***Ex vivo* analysis in whole blood, mean per treatment**



Galápagos

GLPG3970 activity in psoriasis model





###p < 0.0 01
**p<0.05; **p<0.01; ***p<0.001 (vs diseased)*
Pso: psoriasis

Galápagos

Robust activity across arthritis models



****p < 0.001 (vs. diseased)*

CIA: collagen induced arthritis; PsA: psoriatic arthritis
AUC: area under the curve

Galápagos

Robust fibrosis activity *in vivo*





###p < 0.001
**p<0.05; **p<0.01; ***p<0.001 (vs diseased)*

BLM: bleomycin; GvHD: graft versus host disease

Galápagos

Ambitious, informed development strategy

Psoriasis study generates rapid clinical data

Accelerated path taken in PsA based on biology

Rapid progression into Ph2 dose rangers, based on Ph1 PD fingerprints & cross-learnings

Robust program in line with novel pharmacology, investment size, and development stage

Programmatic approach for acceleration to patients

Clinical path

Pso
UC
RA
SLE
pSS

Validating

PsA
RA
UC
CD
AS



Dose-range finding, indication expansion

Phase 3 inflammatory diseases
Fibrosis

Phase 3 + fibrosis

Phase 2b dose-range finding
Phase 2 PoC new indication

Galápagos

Parallel Proof of Concept studies

GLPG3970



5 PoCs to investigate mode of action
Toplines as of mid 2021*

** Timelines subject to delays due to global COVID-19 pandemic*

Galápagos

Fast tracking psoriatic arthritis with ‘3970



Disease area	2021	2022	2023	2024+
Psoriasis	Phase 1b			
Psoriatic arthritis		Phase 2 DRF		Phase 3

Shortens timelines by 18-24 months

DRF = Dose-range finding

Galápagos

CALOSOMA Phase 1b in psoriasis



- Adults with moderate/severe psoriasis (baseline PASI≥12, BSA ≥10%)
- Evaluate safety/tolerability & efficacy GLPG3970 in psoriasis

Galápagos

SEA TURTLE Phase 2 in ulcerative colitis

Sea Turtle



- Adults with moderate/severe active UC (treatment experienced)
- Key outcomes: Mayo clinical score, safety/tolerability, PK & PD efficacy markers

Galápagos

LADYBUG Phase 2 in rheumatoid arthritis

Ladybug



- Patients with moderately/severely active RA & inadequate response to MTX
- Evaluate effect on signs & symptoms of RA, safety & tolerability, PK & PD efficacy markers

Galápagos

Toledo data package convinces

- Target identification data
- Literature evidence
- Preclinical data
- Phase 1 data

Confirmed dual mode of action

Safety package for clinical development

Promising assets

TOLEDO

- Potential master switch for inflammation
- Strong, broad IP protection
- Phase 1 confirms mode of action
- Safety package supports clinical plans
- Smart path in clinical development
- Head start on competition

Key newsflow Toledo

TOLEDO

2021	2022
Readout Ph1 GLPG4399	Readout last 2 PoCs GLPG3970
Readout first 3 PoCs GLPG3970	Readout first Ph2b
	Additional Ph1 readouts

Aim to bring our innovation to patients as fast as possible

Galápagos